Pancreatic cancer has one of the bleakest outlooks of any major cancer — even when surgery successfully removes a tumor, the disease usually comes back. Six-year follow-up data from a small but closely watched trial at Memorial Sloan Kettering Cancer Center suggests a personalized vaccine might be able to change that story for at least some patients.
Key Takeaways
- The vaccine, called autogene cevumeran, is custom-built for each patient using their own tumor’s genetic mutations, and is given after surgery alongside chemotherapy and an immunotherapy drug — not as a standalone treatment.
- In the original 16-person trial, half of the patients developed a strong immune response to the vaccine; the other half didn’t.
- Among the 8 patients who responded, 7 (87.5%) were still alive at the six-year mark. Among the 8 who didn’t respond, only 2 (25%) were alive, with a median survival of 3.4 years.
- This is early-stage, small-sample research — genuinely encouraging, but not yet proof the vaccine prevents recurrence, and a larger Phase 2 trial is now underway to test that more rigorously.
How the Vaccine Actually Works
Led by Dr. Vinod Balachandran, director of the Olayan Center for Cancer Vaccines at MSK, the trial tested whether a personalized mRNA vaccine could train the immune system to hunt down microscopic cancer cells left behind after surgery — the cells responsible for pancreatic cancer’s high recurrence rate. Each patient’s vaccine is custom-built: researchers analyze the specific mutations in that person’s own tumor and design an mRNA blueprint that prompts the body to produce T cells trained to recognize and attack cells carrying those same mutations. Sixteen patients with resectable pancreatic ductal adenocarcinoma received the vaccine starting in December 2019, given alongside standard chemotherapy (FOLFIRINOX) and a checkpoint inhibitor immunotherapy drug called atezolizumab — the vaccine was tested as part of this combination, not on its own.
What the Six-Year Data Actually Shows
The original trial results, published in Nature in February 2025, found that 8 of the 16 patients developed a strong, vaccine-driven T cell response. The new information, presented by Dr. Balachandran at the 2026 American Association for Cancer Research annual meeting, is what happened to those patients over a much longer follow-up window: 7 of the 8 responders (87.5%) were still alive six years after treatment, many without their cancer returning. Among the 8 patients whose immune systems didn’t mount a strong response to the vaccine, only 2 (25%) were still alive, with a median survival of just 3.4 years. “This suggests that personalized vaccines can stimulate the immune system in some pancreatic cancer patients, and that these patients continue to do well for several years after vaccination,” Balachandran said.
That gap between responders and non-responders is the most compelling part of this data — it’s a real, sizable difference, though in a trial this small, a handful of patients moving between groups could meaningfully change the percentages.
Why This Isn’t a Cure Yet
It’s worth being direct about the limits here. Sixteen patients is a genuinely small trial, run at a single institution, without a randomized comparison group receiving surgery and chemotherapy alone. That makes it hard to know for certain how much of the survival difference is attributable to the vaccine itself versus other factors. It’s also not clear yet why half the patients didn’t develop a strong immune response, or how to predict in advance who will. A Phase 2 trial is now underway specifically to test the vaccine’s benefit more rigorously and help identify which patients are most likely to respond — the kind of larger, controlled study needed before this could become a standard treatment.
Why It’s Still a Meaningful Result
Pancreatic cancer’s five-year survival rate sits around just 13%, according to the American Cancer Society, making any therapy that meaningfully extends survival in even a subset of patients a significant development. Dr. Balachandran described the results as showing “the potential to make a difference for one of the deadliest cancers” — notably measured language for early trial data, reflecting genuine promise without overstating what a 16-person study can prove.
Source: Balachandran, V.P., et al. (2025). Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature, 639, 1042-1051; Memorial Sloan Kettering Cancer Center, “Investigational Pancreatic Cancer Vaccine Shows Lasting Results in Early Trial” (2026 AACR follow-up data).